• Cocrystal Pharma on May 26, 2026 disclosed novel direct-acting antivirals with pan-viral activity against hantavirus, bunyavirus, influenza.
• Program targets a conserved region of the viral replication complex, focusing on the L-protein of Andes hantavirus.
• In vitro data showed IC50 below 50 nM against Hantaan virus, a close relative of Andes hantavirus linked to recent outbreaks.
• Next steps include in vitro testing against the Andes hantavirus replication enzyme, aiming to select a pan-viral lead candidate.
• Company also noted CDI-988, a pan-viral protease inhibitor, advanced to a Phase 1b norovirus challenge study in the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.